It has been postulated that the resident "passenger" leukocytes of hematolymphoid origin that migrate from whole organ grafts and subsequently establish systemic chimerism are essential for graft acceptance and the induction of donor-specific nonreactivity. This phenomenon was augmented by infusing 3x lOll unmodified donor bone-marrow cells into 40 patients at the time of organ transplantation. Fifteen of the first 18 analyzable patients had sequential immunological evaluation over postoperative intervals of 5 to 17 months. (which included 7 kidney (two with islets), 7 liver (one with islets), and one heart recipient). The evolution of changes was compared with that in 16 kidney and liver nonmarrow controls followed for 4 to 5 months. The generic immune reactivity of peripheral blood mononuclear cells (PBMC) was determined by their proliferative responses to mitogens (PHA. ConAl. Alloreactivity was measured by the recipient mixed lymphocyte reaction (MLR) to donor and HLA-mismatched third-party panel cells. Based on all 3 tests, I Presented at the 13th Annual ~leetlng of the Amencan ::)ociety of Transplant Physicians, May 16-18. 1994 the recipients were classified as donor-specific hyporeactive, intermediate, and responsive; patients who were globally suppressed made up a fourth category. Eight (53%) of the 15 marrow-treated recipients exhibited progressive modulation of donor-specific reactivity (3 hypo reactive and 5 intermediate) while 7 remained antidonor-responsive. In the nonmarrow controls. 2 (12.5%) of the 16 patients showed donorspecific hyporeactivity, 10 (62.5%) were reactive. and 4 (25%) studied during a CMV infection had global suppression of responsiveness to all stimuli.
We have proposed that the donor bone marrow-derived cells that migrate from transplanted organs and persist in the tissues of long-surviving recipients are essential for graft acceptance and the evolution of donor-specific nonreactlvity ( I, 2). This spontaneous chimerism has been augmented in ·W whole organ recipients by the perioperative infUSIOn of :)x 10"!kg unaltered donor bone marrow cells (3), We report here the sequential immunological evaluation of 15 of the first 18 analyzable recipients. In addition. 16 nonmarrow control recIpients of livers and kidneys were studied. To determine the development of donor specific hyporeactlvity in both cohorts. in vitro tests WE.'re performed monthly with the recipient's peripheral blood mononuclear calls (PBMC).* and the results were correlated with the clinical findings. lcellikg unaltered bone marrow was given a few hours after organ revascularizatlOn (3), Three of the first 18 recipients could not be evaluated. either because they had good MHC matches and consequent donorspecific nonreactivity to begin with (n=2) or because donor cells were not available (n=1). No recipient conditioning was carned out. and postoperative immunosuppression with FK506 and prednisone did not differ from that used routinely (3). The 15 evaluated patients were recipients of 7 kidneys (2 with pancreatic islets I. 7 livers lOne with islets I, and one heart. Using HLA alleles of chromosomes 6 or the Y chromosome (after male-to-female transplants) as markers, all had readily detectable chimerism with F ACS, cytospin, or polymerase chain reaction (PCR) almost invariably with multiple technologies. This was estimated to be at least 1000 times greater than the microchimerism that occurs spontaneously (3).
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Nonmarrow controls: These 16 adults (5 kidney and 11 liver recipients) were from a consecutive series of 19 patients for whom donor bone marrow could not be obtained. The 3 exclusions from the analYSIS were for the same reasons of preexisting nonreactivitv or unavailability of samples as in the marrow group. Immunosuppression and other details of treatment were not different than In the study group. Blood microchimerism was present in 56% of the patients with PCR, but never as in the bone marrow cohort to the level detectable with FACS.
In vitro immune monitoring. Mitogen response assays: PBMC were isolated from the recipient's heparinized blood by FicollHypaque density centrifugation and resuspended at 10 6 cells/ml in tissue culture medium (RPMl 1640) supplemented with 5% pooled normal human serum (.J!. They were then incubated (10 5 Recipients' donor-specific MLR responses at various times posttransplantation were compared with the recipients' pretransplant ! posttransplant:pretransplant donor MLRI as well as with the responses of control third-party (donor MLR:third-party MLR [Di"I'P]I cells. Donor-specific hyporeactivity (category I I was defined as at least a 70% decrease in posttransplant vs. pretransplant donorspecific MLR responses. while maintaining reactivity to both control third-party stimulator cells mrrp ratio < 40%) and to mitogens (>50% of pretransplant responses)' Donor-specific intermediate reactivity (category In was designated when there was a 40-70'} inhibition of antidonor reactivity with retention of third-party responsiveness whereas reactive (category lIli meant that there was minimal or no decline in donor-specific nonreactivity. Suppression (category IV) connoted a nonspecific dimimshed proliferative response to mitogens as well as to alloantigens. Representative examples of each of these 4 categories as measured at 3 postoperative months are shown in Table l .
Limiting dilution analysis (LDA) of donor-specific helper T lymphocytes (HTLl: The frequency of donor-specific HTL was determined according to a previously described method (7). Briefly, vanous dilutions of irradiated recipients' PBMC (250R) were added as responders to round-bottomed microtiter wells that contained 5x 10' irradiated donor cells (2000R) in RPMI supplemented with ,,),} pooled human serum. After 48 hr of incubation at 37°C, an interleukin 2 OL-2)-dependent T cell line (10 3 cells; CTLL-20) was added to each well for an additional 24 hr. Proliferation was measured bv pulsing the cultures for 6 hr with :lH-thymidine. Cultures wer~ considered positive for IL-2 release if cpm exceeded the mean plus 3 SD of 3H-thymidine incorporation in 20 background control wells (microtiter wells that lack the responder cell!. Minimal frequency of HTL was calculated using a computer prO,,"TTam. the use of which has been described previously (8) , and the results were expressed as HTUmillion cells.
Propagation of graft-infiltrating cells: Small fragments of kidney core biopsies were used to propagate alloreactlve T cells in cultur~ (9) .T~e biopsies were teased into 4-fi small fragments and placed in mdlvldual wells of a 96-well round-bottomed microtiter plate in the presence of tissue culture medium supplemented with 5% human serum and 20 U/ml IL-2. Wells were rehTUlarlv observed for cellular proliferation from the biopsy and fed every !ilUrth day With IL-2.
RESULTS
Variability or donor-specijic reactivity. Representative examples of recipients' pre-and posttransplant proliferative responses, classified according to their In vitro reactivitv nre illustrated in Table 1 . Recipient 1 (EM ~ kidnev) exhibited category I "donor-specific hyporeactivity" by th-ree months posttransplant, at which time the MLR response to donor cells was significantly lower than that pretransplant (relative response 13%), whereas the proliferative responses to third-party and mitogens were not suppressed. In contrast, recipient 2 (BM + kidney) was considered a category II "donor-specific intermediate" responder since the donorspecific MLR. though lower. was still 45'70 of pre transplant and the ratio of donor to third-party MLR was greater than '+0%. The Category III example ("reactivity") is exemplified hy BM .,-kidney recipient 3, in whom PBMC responses against the donor or third-party cells remained essentially unchanged. Liver control recipient 4 qualified for category IV (suppressed) because proliferative responses to all stimuli were signIficantly inhibited (this was characteristic during CMV infection). Eight (53'70) of the 15 bone marrow-augmented patients exhibited progressive modulation of donor-specific reactivity, 3 (1 kidnev and 2 livers) with hyporeactivity and 5 (2 kidneys and 3 liv~rs) with intermediate antidonor responses. The other 7, including the heart recipient, remained reactive u to the last date tested (4-6 months postsurgery) ( Table 2) In the nonmarrow control group, 2 (l3o/c-l kidney and liver) of the patients showed donor-specific hyporeactivity, who were studied during or shortly after CMV infection weT suppressed globally, and 10 remained vigorously reactive t donor cells (Table 2) .
Immune reactivity versus immunosuppression and gra[ function. Kidney recipients: The 3 (43%) of the 7 marrow treated recipients showing donor-specific hypo-(or interme diate) reactivity had no evidence of rejection: 2 recipients ar, ofT steroids and the third receives 2.5 mg/day prednison( ( Table 3 ). In contrast, 3 (75%) of the 4 recipients who main tained vigorous antidonor reactivity underwent acute rejec tion episodes and are currently receiving 7.5-12.5 mg/day 0: prednisone. The two pancreatic islet recipients (one exhibit ing intermediate and the other reactive responses against the donor) are additionally receiving 75 mg/day of azathioprine. Both have evidence of plasma C-peptide activity but levels (0.44 and 0.11 pmoVmll are not high enough to permit an insulin-free existence.
All 5 of the nonmarrow control recipients experienced transient rejection episodes. The only one classified as donorspecific hypo reactive is being maintained on FK506 (14 mg! day), prednisone (7.5 mg/day), and azathioprine (125 mg/day) ( Table 3 ). The higher drug requirement and persistently reactive immune status of the patients in the control group may reflect in part their shorter period of follow-up (137 = 24 days) as compared with the patients in the study group (282= 113 days). However, the same general patterns were already identifiable within 90-120 days.
The mean creatinine at the 4-month milestone and at the most recent follow-up was superior in patients in the marrow treated group compared with the controls (1.6=0.5 vs. 2.4+ 1 mgldll. Both groups had similar rates of rejection in the first 4 months (50% vs. 62%) and infection (20% vs. 25%). The (Table 3l . :l.d 1 As reported elsewhere \3), the chimerism was many-fold .y,4 more dense. with an incidence of 100% in the bone marrow >'ere group (one patient who shared 1B and 2 DR loci and same sex e to with the donor could not be followed). compared with lowlevel chimerism in 609c of patients in the control group.
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Liver recipients: A similar pattern was noted in the mar-)W-row-augmented liver recipients compared with controls. The ne-bone marrow cohort had a higher rate of hypo-or intermedilre ate antidonor reactivity \ 71 % vs. 27%), lower doses of immume nosuppression, and a similar incidence of rejection and infecin-tion (Table 4) . Liver function was equivalent in both groups. ec-Interestingly, as in the kidney series, there were no examples of in the bone marrow-treated patients of the global suppresitsion noted in 25% of the controls. study group, whereas donor chimerism was detected in only 54% (6/11) The events were similar in all 3 cases, epitomized by the course of a 25-year-old female recipient of a 5-HLA-matched male kidney (Fig. 1) in whom the presence of the Y chromosome allowed tracking of chimerism. After a bout of steroidtreated rejection on day 16, her recovery was uncomplicated. After 4 months, she had developed donor-specific hyporeactivity. Immunosuppression was reduced on day 175, and prednisone was eventually stopped. On POD 263, the serum creatinine increased, and a biopsy-proven rejection was successfully treated with a steroid bolus and a transient increase in the FK506 dosage (Fig. 1) . The infiltrating cells propagated from the graft biopsy exhibited a 25-fold higher donorspecific alloreactivity than that of the background controls. Two days preceding these events, a blood sample obtained on POD 261 showed an -6-fold increase in donor-specific reactivity. The donor-specific helper T cells <HTL) were found to have increased three-fold from 15/10 6 cells (1 in 65,000 POD 164) to 45110 6 cells (1 in 20,000 POD 232) one month prior to a rejection episode. She still maintains antidonor reactivity at the last date tested (POD 292). However. after successful treatment of rejection, a lymphocyte culture could not be propagated from a follow-up kidney biopsy. Throughout the course, the Y chromosome persisted in the patient's blood samples.
DISCUSSION
The premise upon which this study was based is that donor leukocyte chimerism is the essential basis for organ graft acceptance and the evolution of the donor-specific nonreactivity that follows a characteristic cycle of immunologic crisis and resolution (J, 2l. With the demonstration that this spontaneous chimerism can be reliably and safely increased many-fold by bone marrow augmentation (3), it is possible to envision for the first time a future population of recipients of MHC-incompatible organs who can aspire to a drug-free state.
However, it is equally clear that the enigmatic process leading to donor-specific nonreactivity is very gradual. One of the principal questions asked in this study is if the in vitro immune reactivity profile of the bone marrow treated patients was different. during the first few months, from that resulting from organ transplantation alone. According to the chimerism concept, the same leukocyte-dependent mechanisms of graft acceptance are involved with or without adjuvant bone marrow.
Consequently, it was no surprise that the changes oberved in our marrow cohort were merely magnified and more frequent versions of those also seen in the control population. with no significant differences among recipients of various organs. Similar findings were noted often by others in conventionally treated recipients of various organs (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) , most frequently the liver (22), By themselves, the significance of the more pronounced and more frequent early changes in the bone marrow-augmented recipients would be difficult to assess. However. the remarkable benignancy of recovery in these patients and the accrual of 40 consecutive cases (kidneys, livers, and hearts) with no mortality compared with less-satisfactory results in contemporaneous controls (3) has added to our impression that the marrow enriched recipients' have gained a profound advantage without paying a commensurate penalty. Of special note was the fact that none of the 15 marrow-augmented patients treated with conventional immunosuppression had residual global suppression (category IV) by the time of last testing. The second principal question is whether immunologic monitoring can guide the management of these patients, and provide signals about when it has become safe to wean drugs or stop them. Previous reports have emphasized the poor prediction index of in vitro tests for identification of stable tolerance in animal models (23, 24) or human organ recipients (25). The limitations of such analyses were illustrated by the 3 patients in the present study whose hyporesponsiveness was reversed after premature reductions ofimmunosuppression, with the onset of rejection. Because of the variability of the outbred human population. it is hard to escape the conclusion that an element of trial and error will always be involved no matter how exhaustive the immune monitoring.
Nevertheless, a role for immune monitoring is evident in these trials, if only because of the early warning that it can provide and for its use to assess the response to therapeutic course correction. It goes without saying that these examinations are optimally useful only when they are done serially. Expansion of the test panel to include other methods may prove to be of practical value-and. in addition, these may provide more complete insight about the changes that occur at the interface between the donor and recipient cell populations. both of which retam immunologic reactivity.
